Copyright Reports & Markets. All rights reserved.

Global Metabolic Disorder Therapeutics Market 2019 by Company, Regions, Type and Application, Forecast to 2024

Request for Sample of this report
Buy now

Table of Contents

    1 Metabolic Disorder Therapeutics Market Overview

    • 1.1 Product Overview and Scope of Metabolic Disorder Therapeutics
    • 1.2 Classification of Metabolic Disorder Therapeutics by Types
      • 1.2.1 Global Metabolic Disorder Therapeutics Revenue Comparison by Types (2019-2024)
      • 1.2.2 Global Metabolic Disorder Therapeutics Revenue Market Share by Types in 2018
      • 1.2.3 Lysosomal Storage Diseases
      • 1.2.4 Diabetes
      • 1.2.5 Obesity
      • 1.2.6 Inherited Metabolic Disorders
      • 1.2.7 Hypercholesterolemia
    • 1.3 Global Metabolic Disorder Therapeutics Market by Application
      • 1.3.1 Global Metabolic Disorder Therapeutics Market Size and Market Share Comparison by Applications (2014-2024)
      • 1.3.2 Oral
      • 1.3.3 Parenteral
      • 1.3.4 Others
    • 1.4 Global Metabolic Disorder Therapeutics Market by Regions
      • 1.4.1 Global Metabolic Disorder Therapeutics Market Size (Million USD) Comparison by Regions (2014-2024)
      • 1.4.1 North America (USA, Canada and Mexico) Metabolic Disorder Therapeutics Status and Prospect (2014-2024)
      • 1.4.2 Europe (Germany, France, UK, Russia and Italy) Metabolic Disorder Therapeutics Status and Prospect (2014-2024)
      • 1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Metabolic Disorder Therapeutics Status and Prospect (2014-2024)
      • 1.4.4 South America (Brazil, Argentina, Colombia) Metabolic Disorder Therapeutics Status and Prospect (2014-2024)
      • 1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Metabolic Disorder Therapeutics Status and Prospect (2014-2024)
    • 1.5 Global Market Size of Metabolic Disorder Therapeutics (2014-2024)

    2 Manufacturers Profiles

    • 2.1 Novo Nordisk A/S
      • 2.1.1 Business Overview
      • 2.1.2 Metabolic Disorder Therapeutics Type and Applications
        • 2.1.2.1 Product A
        • 2.1.2.2 Product B
      • 2.1.3 Novo Nordisk A/S Metabolic Disorder Therapeutics Revenue, Gross Margin and Market Share (2017-2018)
    • 2.2 Sanofi S.A.
      • 2.2.1 Business Overview
      • 2.2.2 Metabolic Disorder Therapeutics Type and Applications
        • 2.2.2.1 Product A
        • 2.2.2.2 Product B
      • 2.2.3 Sanofi S.A. Metabolic Disorder Therapeutics Revenue, Gross Margin and Market Share (2017-2018)
    • 2.3 Boehringer Ingelheim GmbH
      • 2.3.1 Business Overview
      • 2.3.2 Metabolic Disorder Therapeutics Type and Applications
        • 2.3.2.1 Product A
        • 2.3.2.2 Product B
      • 2.3.3 Boehringer Ingelheim GmbH Metabolic Disorder Therapeutics Revenue, Gross Margin and Market Share (2017-2018)
    • 2.4 Eli Lilly and Company
      • 2.4.1 Business Overview
      • 2.4.2 Metabolic Disorder Therapeutics Type and Applications
        • 2.4.2.1 Product A
        • 2.4.2.2 Product B
      • 2.4.3 Eli Lilly and Company Metabolic Disorder Therapeutics Revenue, Gross Margin and Market Share (2017-2018)
    • 2.5 Merck KgaA
      • 2.5.1 Business Overview
      • 2.5.2 Metabolic Disorder Therapeutics Type and Applications
        • 2.5.2.1 Product A
        • 2.5.2.2 Product B
      • 2.5.3 Merck KgaA Metabolic Disorder Therapeutics Revenue, Gross Margin and Market Share (2017-2018)
    • 2.6 Amgen, Inc.
      • 2.6.1 Business Overview
      • 2.6.2 Metabolic Disorder Therapeutics Type and Applications
        • 2.6.2.1 Product A
        • 2.6.2.2 Product B
      • 2.6.3 Amgen, Inc. Metabolic Disorder Therapeutics Revenue, Gross Margin and Market Share (2017-2018)
    • 2.7 AstraZeneca PLC
      • 2.7.1 Business Overview
      • 2.7.2 Metabolic Disorder Therapeutics Type and Applications
        • 2.7.2.1 Product A
        • 2.7.2.2 Product B
      • 2.7.3 AstraZeneca PLC Metabolic Disorder Therapeutics Revenue, Gross Margin and Market Share (2017-2018)
    • 2.8 Actelion Pharmaceuticals Ltd.
      • 2.8.1 Business Overview
      • 2.8.2 Metabolic Disorder Therapeutics Type and Applications
        • 2.8.2.1 Product A
        • 2.8.2.2 Product B
      • 2.8.3 Actelion Pharmaceuticals Ltd. Metabolic Disorder Therapeutics Revenue, Gross Margin and Market Share (2017-2018)
    • 2.9 Shire PLC
      • 2.9.1 Business Overview
      • 2.9.2 Metabolic Disorder Therapeutics Type and Applications
        • 2.9.2.1 Product A
        • 2.9.2.2 Product B
      • 2.9.3 Shire PLC Metabolic Disorder Therapeutics Revenue, Gross Margin and Market Share (2017-2018)
    • 2.10 AbbVie, Inc.
      • 2.10.1 Business Overview
      • 2.10.2 Metabolic Disorder Therapeutics Type and Applications
        • 2.10.2.1 Product A
        • 2.10.2.2 Product B
      • 2.10.3 AbbVie, Inc. Metabolic Disorder Therapeutics Revenue, Gross Margin and Market Share (2017-2018)
    • 2.11 Biocon Ltd.
      • 2.11.1 Business Overview
      • 2.11.2 Metabolic Disorder Therapeutics Type and Applications
        • 2.11.2.1 Product A
        • 2.11.2.2 Product B
      • 2.11.3 Biocon Ltd. Metabolic Disorder Therapeutics Revenue, Gross Margin and Market Share (2017-2018)
    • 2.12 BioMarin Pharmaceutical, Inc.
      • 2.12.1 Business Overview
      • 2.12.2 Metabolic Disorder Therapeutics Type and Applications
        • 2.12.2.1 Product A
        • 2.12.2.2 Product B
      • 2.12.3 BioMarin Pharmaceutical, Inc. Metabolic Disorder Therapeutics Revenue, Gross Margin and Market Share (2017-2018)
    • 2.13 Bristol-Myers Squibb Company
      • 2.13.1 Business Overview
      • 2.13.2 Metabolic Disorder Therapeutics Type and Applications
        • 2.13.2.1 Product A
        • 2.13.2.2 Product B
      • 2.13.3 Bristol-Myers Squibb Company Metabolic Disorder Therapeutics Revenue, Gross Margin and Market Share (2017-2018)
    • 2.14 Cipla, Inc.
      • 2.14.1 Business Overview
      • 2.14.2 Metabolic Disorder Therapeutics Type and Applications
        • 2.14.2.1 Product A
        • 2.14.2.2 Product B
      • 2.14.3 Cipla, Inc. Metabolic Disorder Therapeutics Revenue, Gross Margin and Market Share (2017-2018)
    • 2.15 CymaBay Therapeutics, Inc.
      • 2.15.1 Business Overview
      • 2.15.2 Metabolic Disorder Therapeutics Type and Applications
        • 2.15.2.1 Product A
        • 2.15.2.2 Product B
      • 2.15.3 CymaBay Therapeutics, Inc. Metabolic Disorder Therapeutics Revenue, Gross Margin and Market Share (2017-2018)

    3 Global Metabolic Disorder Therapeutics Market Competition, by Players

    • 3.1 Global Metabolic Disorder Therapeutics Revenue and Share by Players (2014-2019)
    • 3.2 Market Concentration Rate
      • 3.2.1 Top 5 Metabolic Disorder Therapeutics Players Market Share
      • 3.2.2 Top 10 Metabolic Disorder Therapeutics Players Market Share
    • 3.3 Market Competition Trend

    4 Global Metabolic Disorder Therapeutics Market Size by Regions

    • 4.1 Global Metabolic Disorder Therapeutics Revenue and Market Share by Regions
    • 4.2 North America Metabolic Disorder Therapeutics Revenue and Growth Rate (2014-2019)
    • 4.3 Europe Metabolic Disorder Therapeutics Revenue and Growth Rate (2014-2019)
    • 4.4 Asia-Pacific Metabolic Disorder Therapeutics Revenue and Growth Rate (2014-2019)
    • 4.5 South America Metabolic Disorder Therapeutics Revenue and Growth Rate (2014-2019)
    • 4.6 Middle East and Africa Metabolic Disorder Therapeutics Revenue and Growth Rate (2014-2019)

    5 North America Metabolic Disorder Therapeutics Revenue by Countries

    • 5.1 North America Metabolic Disorder Therapeutics Revenue by Countries (2014-2019)
    • 5.2 USA Metabolic Disorder Therapeutics Revenue and Growth Rate (2014-2019)
    • 5.3 Canada Metabolic Disorder Therapeutics Revenue and Growth Rate (2014-2019)
    • 5.4 Mexico Metabolic Disorder Therapeutics Revenue and Growth Rate (2014-2019)

    6 Europe Metabolic Disorder Therapeutics Revenue by Countries

    • 6.1 Europe Metabolic Disorder Therapeutics Revenue by Countries (2014-2019)
    • 6.2 Germany Metabolic Disorder Therapeutics Revenue and Growth Rate (2014-2019)
    • 6.3 UK Metabolic Disorder Therapeutics Revenue and Growth Rate (2014-2019)
    • 6.4 France Metabolic Disorder Therapeutics Revenue and Growth Rate (2014-2019)
    • 6.5 Russia Metabolic Disorder Therapeutics Revenue and Growth Rate (2014-2019)
    • 6.6 Italy Metabolic Disorder Therapeutics Revenue and Growth Rate (2014-2019)

    7 Asia-Pacific Metabolic Disorder Therapeutics Revenue by Countries

    • 7.1 Asia-Pacific Metabolic Disorder Therapeutics Revenue by Countries (2014-2019)
    • 7.2 China Metabolic Disorder Therapeutics Revenue and Growth Rate (2014-2019)
    • 7.3 Japan Metabolic Disorder Therapeutics Revenue and Growth Rate (2014-2019)
    • 7.4 Korea Metabolic Disorder Therapeutics Revenue and Growth Rate (2014-2019)
    • 7.5 India Metabolic Disorder Therapeutics Revenue and Growth Rate (2014-2019)
    • 7.6 Southeast Asia Metabolic Disorder Therapeutics Revenue and Growth Rate (2014-2019)

    8 South America Metabolic Disorder Therapeutics Revenue by Countries

    • 8.1 South America Metabolic Disorder Therapeutics Revenue by Countries (2014-2019)
    • 8.2 Brazil Metabolic Disorder Therapeutics Revenue and Growth Rate (2014-2019)
    • 8.3 Argentina Metabolic Disorder Therapeutics Revenue and Growth Rate (2014-2019)
    • 8.4 Colombia Metabolic Disorder Therapeutics Revenue and Growth Rate (2014-2019)

    9 Middle East and Africa Revenue Metabolic Disorder Therapeutics by Countries

    • 9.1 Middle East and Africa Metabolic Disorder Therapeutics Revenue by Countries (2014-2019)
    • 9.2 Saudi Arabia Metabolic Disorder Therapeutics Revenue and Growth Rate (2014-2019)
    • 9.3 UAE Metabolic Disorder Therapeutics Revenue and Growth Rate (2014-2019)
    • 9.4 Egypt Metabolic Disorder Therapeutics Revenue and Growth Rate (2014-2019)
    • 9.5 Nigeria Metabolic Disorder Therapeutics Revenue and Growth Rate (2014-2019)
    • 9.6 South Africa Metabolic Disorder Therapeutics Revenue and Growth Rate (2014-2019)

    10 Global Metabolic Disorder Therapeutics Market Segment by Type

    • 10.1 Global Metabolic Disorder Therapeutics Revenue and Market Share by Type (2014-2019)
    • 10.2 Global Metabolic Disorder Therapeutics Market Forecast by Type (2019-2024)
    • 10.3 Lysosomal Storage Diseases Revenue Growth Rate (2014-2024)
    • 10.4 Diabetes Revenue Growth Rate (2014-2024)
    • 10.5 Obesity Revenue Growth Rate (2014-2024)
    • 10.6 Inherited Metabolic Disorders Revenue Growth Rate (2014-2024)
    • 10.7 Hypercholesterolemia Revenue Growth Rate (2014-2024)

    11 Global Metabolic Disorder Therapeutics Market Segment by Application

    • 11.1 Global Metabolic Disorder Therapeutics Revenue Market Share by Application (2014-2019)
    • 11.2 Metabolic Disorder Therapeutics Market Forecast by Application (2019-2024)
    • 11.3 Oral Revenue Growth (2014-2019)
    • 11.4 Parenteral Revenue Growth (2014-2019)
    • 11.5 Others Revenue Growth (2014-2019)

    12 Global Metabolic Disorder Therapeutics Market Size Forecast (2019-2024)

    • 12.1 Global Metabolic Disorder Therapeutics Market Size Forecast (2019-2024)
    • 12.2 Global Metabolic Disorder Therapeutics Market Forecast by Regions (2019-2024)
    • 12.3 North America Metabolic Disorder Therapeutics Revenue Market Forecast (2019-2024)
    • 12.4 Europe Metabolic Disorder Therapeutics Revenue Market Forecast (2019-2024)
    • 12.5 Asia-Pacific Metabolic Disorder Therapeutics Revenue Market Forecast (2019-2024)
    • 12.6 South America Metabolic Disorder Therapeutics Revenue Market Forecast (2019-2024)
    • 12.7 Middle East and Africa Metabolic Disorder Therapeutics Revenue Market Forecast (2019-2024)

    13 Research Findings and Conclusion

      14 Appendix

      • 14.1 Methodology

      Scope of the Report:
      Increasing demand for one-time therapies for metabolic disorders and rising prevalence of lifestyle diseases are the key factors that are expected to boost the growth of this market.
      The global Metabolic Disorder Therapeutics market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2024, growing at a CAGR of xx% between 2019 and 2024.
      The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
      North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Metabolic Disorder Therapeutics.
      Europe also play important roles in global market, with market size of xx million USD in 2019 and will be xx million USD in 2024, with a CAGR of xx%.
      This report studies the Metabolic Disorder Therapeutics market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Metabolic Disorder Therapeutics market by product type and applications/end industries.

      Market Segment by Companies, this report covers
      Novo Nordisk A/S
      Sanofi S.A.
      Boehringer Ingelheim GmbH
      Eli Lilly and Company
      Merck KgaA
      Amgen, Inc.
      AstraZeneca PLC
      Actelion Pharmaceuticals Ltd.
      Shire PLC
      AbbVie, Inc.
      Biocon Ltd.
      BioMarin Pharmaceutical, Inc.
      Bristol-Myers Squibb Company
      Cipla, Inc.
      CymaBay Therapeutics, Inc.

      Market Segment by Regions, regional analysis covers
      North America (United States, Canada and Mexico)
      Europe (Germany, France, UK, Russia and Italy)
      Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
      South America (Brazil, Argentina, Colombia)
      Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

      Market Segment by Type, covers
      Lysosomal Storage Diseases
      Diabetes
      Obesity
      Inherited Metabolic Disorders
      Hypercholesterolemia

      Market Segment by Applications, can be divided into
      Oral
      Parenteral
      Others

      Buy now